Drug Patents owned by Salix

1. List of Fenoglide drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9173847 SALIX Tablet comprising a fibrate
Oct, 2024

(1 year, 6 months from now)

US8481078 SALIX Solid dosage form comprising a fibrate
Oct, 2024

(1 year, 6 months from now)

US8124125 SALIX Solid dosage form comprising a fibrate
Oct, 2024

(1 year, 6 months from now)

US7658944 SALIX Solid dosage form comprising a fibrate
Dec, 2024

(1 year, 8 months from now)

Drugs and Companies using FENOFIBRATE ingredient

Market Authorisation Date: 10 August, 2007

Treatment: Use of fenofibrate for reducing elevated total cholesterol (total-c), ldl-c, apo-lipoprotein b, or total triglycerides; For reducing total cholesterol (total-c), ldl-c, apo-lipoprotein b, or total tri...

Dosage: TABLET;ORAL

How can I launch a generic of FENOGLIDE before it's patent expiration?
More Information on Dosage

FENOGLIDE family patents

14

United States

13

Denmark

5

European Union

4

Canada

3

Korea, Republic of

2

Japan

2

Australia

2

China

1

Hong Kong

1

Russia

1

Brazil

1

Mexico

2. List of Plenvu drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11529368 SALIX Colonoscopy—preparation
Mar, 2032

(8 years from now)

US10792306 SALIX Colonoscopy—preparation
Mar, 2032

(8 years from now)

US10780112 SALIX Colonoscopy-preparation
Mar, 2032

(8 years from now)

US10646512 SALIX Colonoscopy - preparation
Mar, 2032

(9 years from now)

US9592252 SALIX Colonoscopy—preparation
Aug, 2032

(9 years from now)

US8999313 SALIX Compositions
Sep, 2033

(10 years from now)

US10918723 SALIX Colon cleansing compositions and methods of use
Sep, 2033

(10 years from now)

US10016504 SALIX Compositions
Sep, 2033

(10 years from now)

US9707297 SALIX Compositions
Sep, 2033

(10 years from now)

US9326969 SALIX Compositions
Sep, 2033

(10 years from now)

Drugs and Companies using ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE ingredient

Market Authorisation Date: 04 May, 2018

Treatment: For cleansing of the colon in preparation for colonoscopy in adults

Dosage: FOR SOLUTION;ORAL

How can I launch a generic of PLENVU before it's patent expiration?
More Information on Dosage

PLENVU family patents

17

United States

8

European Union

7

Korea, Republic of

6

Israel

6

South Africa

6

Australia

6

Singapore

6

Spain

6

China

6

Japan

5

Denmark

5

Portugal

5

United Kingdom

4

Poland

EA

4

EA

4

Canada

3

Mexico

3

Slovenia

3

Lithuania

3

Hungary

3

Croatia

3

Brazil

3

Malaysia

3

Taiwan, Province of China

3

RS

3

Ukraine

3

New Zealand

2

Hong Kong

2

Argentina

2

ME

1

Ireland

1

Finland

1

Cyprus

1

Netherlands

1

San Marino

1

India

3. List of Relistor drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8420663 SALIX Peripheral opioid receptor antagonists and uses thereof
Sep, 2029

(6 years from now)

US9492445 SALIX Peripheral opioid receptor antagonists and uses thereof
Sep, 2029

(6 years from now)

US9180125 SALIX Peripheral opioid receptor antagonists and uses thereof
Sep, 2029

(6 years from now)

US9724343 SALIX Peripheral opioid receptor antagonists and uses thereof
Sep, 2029

(6 years from now)

US8956651 SALIX Oral formulations and lipophilic salts of methylnal trexone
Mar, 2031

(7 years from now)

US10376505 SALIX Oral formulations and lipophilic salts of methylnaltrexone
Mar, 2031

(7 years from now)

US9314461 SALIX Oral formulations and lipophilic salts of methylnaltrexone
Mar, 2031

(7 years from now)

US10307417 SALIX Oral formulations and lipophilic salts of methylnaltrexone
Mar, 2031

(7 years from now)

US8524276 SALIX Oral formulations and lipophilic salts of methylnaltrexone
Mar, 2031

(7 years from now)

Drugs and Companies using METHYLNALTREXONE BROMIDE ingredient

Market Authorisation Date: 19 July, 2016

Treatment: Treatment of opioid-induced constipation

Dosage: TABLET;ORAL

How can I launch a generic of RELISTOR before it's patent expiration?
More Information on Dosage

RELISTOR family patents

21

United States

9

Japan

7

New Zealand

6

European Union

5

China

4

Singapore

4

Korea, Republic of

3

Israel

3

Mexico

3

Brazil

3

Poland

2

Australia

2

Hong Kong

2

Russia

2

Argentina

2

Spain

2

Taiwan, Province of China

2

Ukraine

2

Canada

1

South Africa

1

Morocco

1

Hungary

1

Costa Rica

1

Colombia

1

Portugal

1

Guatemala

1

Malaysia

1

Peru

1

Chile

1

Ecuador

1

Georgia

EA

1

EA

1

Tunisia

4. List of Trulance drug patents

TRULANCE's oppositions filed in EPO
TRULANCE Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7799897 SALIX Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
Jun, 2022

(9 months ago)

US7041786 SALIX Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
Jan, 2028

(4 years from now)

US10011637 SALIX Ultra-pure agonists of guanylate cyclase C, method of making and using same
Jun, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8637451 SALIX Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
Mar, 2022

(11 months ago)

US9925231 SALIX Formulations of guanylate cyclase C agonists and methods of use
Sep, 2031

(8 years from now)

US9919024 SALIX Formulations of guanylate cyclase C agonists and methods of use
Sep, 2031

(8 years from now)

US9610321 SALIX Formulations of guanylate cyclase C agonists and methods of use
Sep, 2031

(8 years from now)

US11319346 SALIX Ultra-pure agonists of guanylate cyclase C, method of making and using same
Mar, 2032

(8 years from now)

US9616097 SALIX Formulations of guanylate cyclase C agonists and methods of use
Aug, 2032

(9 years from now)

US11142549 SALIX Ultra-pure agonists of guanylate cyclase C, method of making and using same
Jun, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 19, 2022

Drugs and Companies using PLECANATIDE ingredient

NCE-1 date: 2021-01-19

Market Authorisation Date: 19 January, 2017

Treatment: Elevation of intracellular cgmp resulting in increased intestinal fluid and accelerated transit; Irritable bowel syndrome with constipation; Chronic idiopathic constipation

Dosage: TABLET;ORAL

How can I launch a generic of TRULANCE before it's patent expiration?
More Information on Dosage

TRULANCE family patents

36

United States

9

Japan

8

Australia

8

European Union

7

China

6

Canada

5

Hong Kong

4

Spain

EA

3

EA

1

Israel

1

Germany

1

Brazil

1

Portugal

1

Denmark

1

Cyprus

1

Korea, Republic of

5. List of Uceris drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10660858 SALIX Controlled release and taste masking oral pharmaceutical composition
Sep, 2031

(8 years from now)

US8895064 SALIX Controlled release and taste masking oral pharmaceutical composition
Sep, 2031

(8 years from now)

US9192581 SALIX Controlled release and taste masking oral pharmaceutical composition
Sep, 2031

(8 years from now)

US10307375 SALIX Controlled release and taste masking oral pharmaceutical composition
Sep, 2031

(8 years from now)

US9132093 SALIX Controlled release and taste making oral pharmaceutical composition
Sep, 2031

(8 years from now)

Drugs and Companies using BUDESONIDE ingredient

Market Authorisation Date: 14 January, 2013

Treatment: Induction of remission in patients with active, mild to moderate ulcerative colitis

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of UCERIS before it's patent expiration?
More Information on Dosage

UCERIS family patents

34

United States

3

Japan

2

Italy

2

European Union

1

Germany

1

Hong Kong

1

Russia

1

Portugal

1

Denmark

1

Austria

1

Turkey

1

Mexico

1

Spain

1

Canada

1

Norway

1

Australia

1

China

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in